retatrutide study near me Eli Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments ESC 2024: Retatrutide improves lipid
Description
Bottom line: Breaking a GLP-1 weight loss plateau is possible, but whether you should depends on your goals, health, and what feels sustainable in the long term
Targets stubborn fatreduces a double chin or excess fat along the jawline
Dose escalation should proceed slowly if dizziness emerges
GLP-1 helps lower blood sugar, slows digestion, and reduces hunger, while GIP enhances insulin release and may amplify weight loss when combined with GLP-1
Some of the GLP-1s approved to treat T2D, such as Ozempic, are also widely known to be used for weight loss
